442 related articles for article (PubMed ID: 23045324)
21. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
Pathak HB; Zhou Y; Sethi G; Hirst J; Schilder RJ; Golemis EA; Godwin AK
PLoS One; 2015; 10(12):e0144126. PubMed ID: 26637171
[TBL] [Abstract][Full Text] [Related]
22. To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.
Lipkowitz S; Kohn EC
J Clin Oncol; 2015 Dec; 33(35):4127-8. PubMed ID: 26438113
[No Abstract] [Full Text] [Related]
23. Hormonal therapy in epithelial ovarian cancer.
Rao GG; Miller DS
Expert Rev Anticancer Ther; 2006 Jan; 6(1):43-7. PubMed ID: 16375643
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
Sheng Q; Liu J
Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
[TBL] [Abstract][Full Text] [Related]
25. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
Ajani MA; Salami A; Awolude OA; Oluwasola AO
Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
[TBL] [Abstract][Full Text] [Related]
26. Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.
Kohan-Ivani K; Gabler F; Selman A; Vega M; Romero C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):47-58. PubMed ID: 26091707
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.
de Toledo MC; Sarian LO; Sallum LF; Andrade LL; Vassallo J; de Paiva Silva GR; Pinto GA; Soares FA; Fonseca CD; Derchain SF
Acta Histochem; 2014 Apr; 116(3):440-7. PubMed ID: 24238473
[TBL] [Abstract][Full Text] [Related]
28. Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.
Sankpal UT; Ingersoll SB; Ahmad S; Holloway RW; Bhat VB; Simecka JW; Daniel L; Kariali E; Vishwanatha JK; Basha R
Tumour Biol; 2016 Oct; 37(10):14259-14269. PubMed ID: 27581819
[TBL] [Abstract][Full Text] [Related]
29. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
[TBL] [Abstract][Full Text] [Related]
30. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Grabosch S; Tseng G; Edwards RP; Lankes HA; Moore K; Odunsi K; Vlad A; Ma T; Strange M; Brozick J; Lugade A; Omilian A; Bshara W; Stuckey AR; Walker JL; Birrer M
Gynecol Oncol; 2017 Jul; 146(1):137-145. PubMed ID: 28483269
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
Eeles RA; Morden JP; Gore M; Mansi J; Glees J; Wenczl M; Williams C; Kitchener H; Osborne R; Guthrie D; Harper P; Bliss JM
J Clin Oncol; 2015 Dec; 33(35):4138-44. PubMed ID: 26417001
[TBL] [Abstract][Full Text] [Related]
32. Novel agents in ovarian cancer.
Matei D
Expert Opin Investig Drugs; 2007 Aug; 16(8):1227-39. PubMed ID: 17685871
[TBL] [Abstract][Full Text] [Related]
33. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
36. Targeting signaling pathways in epithelial ovarian cancer.
Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J
Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor and epithelial ovarian cancer.
Yokoyama Y; Mizunuma H
Eur J Gynaecol Oncol; 2010; 31(6):612-5. PubMed ID: 21319501
[No Abstract] [Full Text] [Related]
38. Hormone therapy in epithelial ovarian cancer.
Makar AP
Endocr Relat Cancer; 2000 Jun; 7(2):85-93. PubMed ID: 10903526
[TBL] [Abstract][Full Text] [Related]
39. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Kumar J; Fraser FW; Riley C; Ahmed N; McCulloch DR; Ward AC
Br J Cancer; 2014 Jan; 110(1):133-45. PubMed ID: 24220695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
